EP1093368A4 - INDOLE AND TETRAHYDROISOQUINOLINE CONTAINING $g(a)-KETO OXADIAZOLES AS SERINE PROTEASE INHIBITORS - Google Patents

INDOLE AND TETRAHYDROISOQUINOLINE CONTAINING $g(a)-KETO OXADIAZOLES AS SERINE PROTEASE INHIBITORS

Info

Publication number
EP1093368A4
EP1093368A4 EP99927189A EP99927189A EP1093368A4 EP 1093368 A4 EP1093368 A4 EP 1093368A4 EP 99927189 A EP99927189 A EP 99927189A EP 99927189 A EP99927189 A EP 99927189A EP 1093368 A4 EP1093368 A4 EP 1093368A4
Authority
EP
European Patent Office
Prior art keywords
oxadiazoles
tetrahydroisoquinoline
keto
indole
protease inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99927189A
Other languages
German (de)
French (fr)
Other versions
EP1093368A1 (en
Inventor
Lyle Spruce
Albert Gyorkos
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ono Pharmaceutical Co Ltd
Cortech Inc
Original Assignee
Ono Pharmaceutical Co Ltd
Cortech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/089,587 external-priority patent/US6100238A/en
Application filed by Ono Pharmaceutical Co Ltd, Cortech Inc filed Critical Ono Pharmaceutical Co Ltd
Priority to EP01200500A priority Critical patent/EP1114822A3/en
Publication of EP1093368A1 publication Critical patent/EP1093368A1/en
Publication of EP1093368A4 publication Critical patent/EP1093368A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP99927189A 1998-06-03 1999-06-03 INDOLE AND TETRAHYDROISOQUINOLINE CONTAINING $g(a)-KETO OXADIAZOLES AS SERINE PROTEASE INHIBITORS Withdrawn EP1093368A4 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP01200500A EP1114822A3 (en) 1998-06-03 1999-06-03 Indoles and tetrahydroisoquinolines containing alpha-keto oxadiazoles as serine protease inhibitors

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
1996-11-18
US09/089,587 US6100238A (en) 1994-11-21 1998-06-03 Indole and tetrahydroisoquinoline containing Alpha-keto oxadiazoles as serine protease inhibitors
PCT/US1999/012352 WO1999062514A1 (en) 1998-06-03 1999-06-03 INDOLE AND TETRAHYDROISOQUINOLINE CONTAINING α-KETO OXADIAZOLES AS SERINE PROTEASE INHIBITORS

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP01200500A Division EP1114822A3 (en) 1998-06-03 1999-06-03 Indoles and tetrahydroisoquinolines containing alpha-keto oxadiazoles as serine protease inhibitors

Publications (2)

Publication Number Publication Date
EP1093368A1 EP1093368A1 (en) 2001-04-25
EP1093368A4 true EP1093368A4 (en) 2002-11-13

Family

ID=26780737

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99927189A Withdrawn EP1093368A4 (en) 1998-06-03 1999-06-03 INDOLE AND TETRAHYDROISOQUINOLINE CONTAINING $g(a)-KETO OXADIAZOLES AS SERINE PROTEASE INHIBITORS

Country Status (4)

Country Link
EP (1) EP1093368A4 (en)
JP (1) JP2004517028A (en)
KR (1) KR20010078724A (en)
WO (1) WO1999062514A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA200901082A1 (en) * 2007-02-09 2010-02-26 Айрм Ллк COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS ACTIVATING CHANNELS
AU2020349353A1 (en) 2019-09-17 2022-04-14 Duke University Alvelestat for use in the treatment of graft rejection, bronchiolitis obliterans syndrome and graft versus host disease
US20230218596A1 (en) 2020-04-16 2023-07-13 Mereo Biopharma 4 Limited Methods involving neutrophil elastase inhibitor alvelestat for treating coronavirus infection
WO2023067103A1 (en) 2021-10-20 2023-04-27 Mereo Biopharma 4 Limited Neutrophil elastase inhibitors for use in the treatment of fibrosis

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993020099A2 (en) * 1992-03-27 1993-10-14 Ferring B.V. Cck and/or gastrin receptor ligands
WO1996016080A1 (en) * 1994-11-21 1996-05-30 Cortech, Inc. Human neutrophil elastase inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993020099A2 (en) * 1992-03-27 1993-10-14 Ferring B.V. Cck and/or gastrin receptor ligands
WO1996016080A1 (en) * 1994-11-21 1996-05-30 Cortech, Inc. Human neutrophil elastase inhibitors
US5618792A (en) * 1994-11-21 1997-04-08 Cortech, Inc. Substituted heterocyclic compounds useful as inhibitors of (serine proteases) human neutrophil elastase

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO9962514A1 *

Also Published As

Publication number Publication date
EP1093368A1 (en) 2001-04-25
WO1999062514A1 (en) 1999-12-09
JP2004517028A (en) 2004-06-10
KR20010078724A (en) 2001-08-21

Similar Documents

Publication Publication Date Title
AU4330899A (en) Peptoid and nonpeptoid containing alpha-keto oxadiazoles as serine protease inhibitors
ZA983629B (en) Serine protease inhibitors
PL331533A1 (en) Cysteine protease inhibitors
PL349192A1 (en) Protease inhibitors
EP1021199A4 (en) PEPTIDE-CONTAINING $g(a)-KETOAMIDE CYSTEINE AND SERINE PROTEASE INHIBITORS
ZA951573B (en) Cysteine protease inhibitors
IL142398A0 (en) Serine protease inhibitor
AU4236796A (en) Cysteine protease and serine protease inhibitors
IL128662A0 (en) Heterocyclic metalloprotease inhibitors
HK1039159A1 (en) Multyply-substitued protease variants
HUP0101484A3 (en) Quinolones as serine protease inhibitors and medicaments containing them
EP0923535A4 (en) Inhibitors of cysteine protease
IL120311A0 (en) Serine protease inhibitors and pharmaceutical compositions containing them
PL328875A1 (en) Serinic protease inhibitors
AU7179598A (en) Benzothiazo and related heterocyclic group-containing cysteine and serine protease inhibitors
IL139187A0 (en) Cysteine protease inhibitors
EP1067894A4 (en) Protease inhibitors
HK1039276A1 (en) Hydroxamate-containing cysteine and serine protease inhibitors
EP1079821A4 (en) Protease inhibitors
GB9800817D0 (en) Serine protease inhibitors
EP1093368A4 (en) INDOLE AND TETRAHYDROISOQUINOLINE CONTAINING $g(a)-KETO OXADIAZOLES AS SERINE PROTEASE INHIBITORS
EP1140897A4 (en) Protease inhibitors
EP1086083A4 (en) Protease inhibitors
GB9603217D0 (en) Serine protease inhibitors
AU4415799A (en) Indole and tetrahydroisoquinoline containing alpha-keto oxadiazoles as serine protease inhibitors

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20001228

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL PAYMENT 20001228;LT PAYMENT 20001228;LV PAYMENT 20001228;MK PAYMENT 20001228;RO PAYMENT 20001228;SI PAYMENT 20001228

A4 Supplementary search report drawn up and despatched

Effective date: 20020930

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 7C 07D 413/12 A, 7A 61K 31/405 B, 7A 61K 31/41 B, 7A 61K 31/47 B, 7C 07D 217/12 B, 7C 07D 217/16 B, 7C 07D 249/08 B, 7C 07D 271/06 B, 7C 07D 271/10 B

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20051201

R18D Application deemed to be withdrawn (corrected)

Effective date: 20060103